iRhythm Holdings Earnings Call Transcripts
Fiscal Year 2026
-
A recent cybersecurity incident was contained without operational or financial impact, and regulatory timelines remain intact. Zio MCT's FDA submission is on track for a first half 2027 launch, with a new mobile gateway and significant AI-driven efficiency gains expected. Innovative channel partners are driving the fastest revenue growth, and regulatory remediation efforts are progressing.
-
Cardiac monitoring market share continues to grow, driven by product innovation, primary care expansion, and international opportunities. FDA clearance of a third-generation algorithm and strong Q1 financials support raised guidance and long-term margin goals.
-
The meeting covered director elections, approval of the 2026 Equity Incentive Plan, amendments to governance documents, auditor ratification, and executive compensation. All proposals passed, and stockholder questions will be addressed post-meeting.
-
LCD updates expanded patient access and Q1 delivered strong revenue and margin growth, led by Zio Monitor and innovative channels. AI-driven efficiencies and new product launches are expected to drive further margin gains, while international and innovative channel expansion remain key growth areas.
-
Q1 2026 saw 25.7% revenue growth, margin expansion, and improved profitability, driven by strong volume across core and emerging channels. Guidance for 2026 was raised, with continued investment in AI, workflow integration, and international growth.
-
Proactive arrhythmia detection and AI-driven predictive tools are expanding market reach, with strong growth in primary care and international markets. Record 2025 revenue and profitability set the stage for 17–18% growth in 2026, supported by new product launches and operational efficiencies.
Fiscal Year 2025
-
Delivered record 2025 revenue growth of 26%, first-ever positive net income and free cash flow, and expanded margins, driven by strong volume across all channels and operational efficiencies. 2026 guidance calls for 16–18% revenue growth and further margin expansion.
-
Cardiac monitoring solutions are driving strong growth, with revenue acceleration in 2025 fueled by product innovation, EHR integration, and proactive monitoring channels. Favorable reimbursement trends and a robust product pipeline support a positive outlook, with margin expansion and new market opportunities ahead.
-
Ambulatory cardiac monitoring is experiencing robust growth, driven by primary care adoption, workflow innovation, and proactive risk-based partnerships. International expansion and product innovation, including AI and multi-vitals platforms, are set to drive future growth, with profitability and revenue guidance reflecting a balanced, data-driven approach.
-
The conference highlighted strong revenue growth, expanding market share, and robust international expansion, driven by innovative AI-powered cardiac monitoring solutions. Strategic partnerships, EHR integration, and a multivitals platform underpin future growth and profitability.
-
Management addressed draft LCD concerns, reaffirmed confidence in regulatory outcomes, and highlighted strong 2025 growth driven by XT, AT, and innovative channel partners. Next-gen MCT is on track for a 2026 launch, and international expansion efforts focus on Japan despite reimbursement hurdles.
-
Q3 2025 saw 31% revenue growth to $192.9M, record performance in Zio Monitor and AT, and improved profitability with an 11.2% adjusted EBITDA margin. Guidance for 2025 was raised, with free cash flow positive expected for the year and strong momentum across all business segments.
-
Core business momentum, expanding primary care adoption, and innovative channels are driving growth, with AI and new partnerships broadening the market opportunity. Regulatory progress and operational investments support a path to higher margins and market share, especially with the upcoming MCT launch.
-
Strong Q2 results were driven by core business momentum, larger new accounts, and increased integration with health networks. Product innovation continues with the NCT filing and expansion into asymptomatic monitoring, supported by AI and virtual care. International growth and platform expansion into sleep diagnosis present further opportunities.
-
Growth is accelerating in long-term continuous monitoring, driven by clinical evidence, new accounts, and EHR integration, with over 70% market share in LTCM and strong expansion into primary care. Zio MCT is nearing FDA submission, aiming for significant share gains, while innovative channel partnerships and international markets offer additional long-term opportunities.
-
Q2 2025 revenue grew 26% year-over-year to $186.7M, driven by core business, Zio AT, and innovative channels. Raised full-year guidance to $720–$730M, with improved margins and strong international momentum. AI partnerships and new product launches support long-term growth.
-
Growth accelerated in 2024, driven by strong LTCM share, expanding primary care penetration, and clinical evidence supporting market access. Zio MCT submission is on track for Q3 2025, with remediation efforts nearing completion and new adjacent market pilots planned.
-
Strong market share gains in long-term cardiac monitoring, innovative channel expansion, and superior product performance have driven two consecutive quarters of 20%+ growth. Regulatory progress, operational efficiencies, and a robust pipeline support a positive outlook for continued expansion and profitability.
-
AI-driven personalized medicine and long-term cardiac monitoring are fueling strong growth, with revenue up over 20% and expanding international presence. Strategic focus on primary care, innovation, and operational excellence positions the business for continued market leadership.
-
Strong Q1 results and raised 2025 guidance were driven by Zio AT's sustained growth and market share gains. Operational improvements, Epic EHR integration, and primary care expansion are supporting volume growth, while new product launches and strategic initiatives position the company for continued margin and cash flow improvement.
-
Q1 2025 revenue grew 20.3% year-over-year to $158.7M, driven by strong Zio AT and Monitor demand, primary care expansion, and international growth. Full-year guidance was raised to $690–$700M, with improved EBITDA margin outlook and robust cash reserves.
-
The company is accelerating growth through primary care expansion, international launches, and product innovation, including a new multi-modal sensing platform. Operational improvements and strong AI-driven diagnostics support a positive financial outlook, with 2025 revenue guidance of $675M–$685M.
Fiscal Year 2024
-
Revenue grew 24% year-over-year in Q4 2024, driven by record account openings, primary care expansion, and international launches. Gross margin improved to 70%, and adjusted EBITDA margin reached 11.7%. 2025 guidance anticipates continued volume growth, flat gross margin, and 7–8% adjusted EBITDA margin.
-
Patch-based cardiac monitoring is rapidly gaining share, with strong growth in primary care and international markets. Regulatory remediation is on track, and new product launches and automation are expected to drive margin and revenue growth, with a billion-dollar target in sight.
-
Regulatory progress continues with two 510(k) clearances and a comprehensive quality overhaul extending through 2025. Market share gains are driven by product advantages and commercial execution, while primary care and innovative screening approaches fuel expansion. Margin improvements are expected as operations scale and transition to Zio Monitor completes.
-
Q3 2024 revenue grew 18.4% year-over-year to $147.5M, driven by record demand and new accounts. Regulatory remediation advanced with two FDA clearances, but Zio MCT submission is delayed to Q3 2025, impacting 2025 revenue. Strong cash position and international expansion continue.
-
Leadership is optimistic about growth, driven by innovation, international expansion, and new partnerships. Regulatory remediation is a top priority, with key FDA submissions progressing. Full-year guidance is reiterated, and new market opportunities in primary care and international markets are expected to drive future growth.
-
Q3 volumes followed seasonal trends, with strong late-summer performance and full-year guidance reaffirmed. Regulatory remediation is the top priority, with FDA alignment and 510(k) approvals expected soon. International expansion and new technology partnerships are set to drive growth into 2025.
-
A new partnership with BioIntelliSense will expand sensing capabilities and support entry into sleep and respiratory markets, while FDA remediation and MCT platform development remain top priorities. Regulatory progress in Japan and Europe, plus workflow integration with Epic and Signify, are set to drive growth through 2025.
-
Q2 2024 revenue grew 19.3% year-over-year to $148 million, with strong volume and margin gains. Raised full-year guidance across all metrics, advanced regulatory submissions, and expanded payer coverage, while addressing ongoing FDA and DOJ matters.
-
Ambulatory cardiac monitoring is expanding, with long-term continuous monitoring leading growth and significant share gains. International expansion, new partnerships, and the next-gen Zio MCT device are set to drive further acceleration, especially in 2025.
-
AI-powered cardiac monitoring platform is rapidly expanding in primary care and international markets, with strong financial momentum, new product launches, and strategic partnerships. Growth is expected to accelerate as regulatory and operational milestones are achieved.